ALTEOGEN Inc. (KOSDAQ:196170)
South Korea
· Delayed Price · Currency is KRW 345,000
-7,500 (-2.13%)
May 9, 2025, 3:30 PM KST
ALTEOGEN Revenue
In the year 2024, ALTEOGEN had annual revenue of 102.85B KRW with 6.56% growth. ALTEOGEN had revenue of 50.83B in the quarter ending December 31, 2024, with 127.42% growth.
Revenue
102.85B
Revenue Growth
+6.56%
P/S Ratio
178.77
Revenue / Employee
709.34M
Employees
145
Market Cap
18.39T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 102.85B | 6.33B | 6.56% |
| Dec 31, 2023 | 96.52B | 67.72B | 235.08% |
| Dec 31, 2022 | 28.81B | -9.94B | -25.65% |
| Dec 31, 2021 | 38.75B | -3.68B | -8.67% |
| Dec 31, 2020 | 42.43B | 13.20B | 45.15% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 68.13B |
| PharmaResearch | 350.12B |
| Peptron | 3.15B |
| LigaChem Biosciences | 125.90B |